We are driven by the passion to nurture and preserve the precious moments of everyday life for all people, regardless of their health condition. From treatment to disease prevention, we will continue to develop innovative new drugs that contribute to better health and bring smiles to the faces of people everywhere.
Latest News
-
July 10, 2025
News Releases
Taiho Pharmaceutical and Taiho Oncology Announce U.S. FDA Acceptance of Supplemental New Drug Application for INQOVI® in Combination with Venetoclax to Treat Patients with Acute Myeloid Leukemia
-
July 08, 2025
News Releases
Phase III Clinical Study with Therapeutic Drug for Duchenne Muscular Dystrophy (TAS-205) in Japan Did Not Meet Its Primary Endpoint
-
June 04, 2025
News Releases
Taiho Pharmaceutical and SyntheticGestalt Implements Technology Validation Towards Generative AI-Driven Expansion of Cysteinomix Drug Discovery Platform
-
June 02, 2025
News Releases
Taiho Pharmaceutical Out-Licenses LSD1 Inhibitor, TAS1440 to Benz Sciences
-
May 23, 2025
News Releases
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT Trial of Zipalertinib at ASCO 2025
-
April 30, 2025
Information
Otsuka Holdings announces 1Q FY2025 financial results
-
June 07, 2024
Information
Otsuka Holdings announces Fourth Medium-Term Management Plan(2024-2028)
-
January 09, 2024
Information
Donations to Support Relief Efforts Following the Noto Peninsula Earthquake
-
February 22, 2023
Information
Donations to Support Relief Efforts Following Earthquakes in Turkey and Syria
-
March 17, 2022
Information
■Otsuka Holdings Donations for Humanitarian Support to Ukrainian People
-
July 12, 2018
Information
Announcement of Support from Otsuka Holdings and Its Group Companies in the Aftermath of Severe Storms in Japan（PDF：165.9 KB）
MOVIE
TAIHO PHARMA STORY
Introducing Taiho Pharmaceutical’s history and its unique approaches in R&D.
This video is not intended to constitute promotion or advertisement of any products.